Document is current
Any future updates will be listed below
-
Authors
Alcon, Clara
Martín, Fernando http://orcid.org/0000-0002-3496-9093
Prada, Estela http://orcid.org/0000-0003-4611-1120
Mora, Jaume
Soriano, Aroa http://orcid.org/0000-0001-9659-1471
Guillén, Gabriela http://orcid.org/0000-0001-5632-2672
Gallego, Soledad http://orcid.org/0000-0002-4712-9624
Roma, Josep http://orcid.org/0000-0001-7692-6123
Samitier, Josep http://orcid.org/0000-0002-1140-3679
Villanueva, Alberto http://orcid.org/0000-0001-5164-0006
Montero, Joan http://orcid.org/0000-0002-9192-4836
- License Information
-
More Information
Article History
Received: 4 November 2021
Revised: 18 February 2022
Accepted: 16 March 2022
First Online: 7 April 2022
Conflict of interest
: JM was a paid consultant for Oncoheroes Biosciences and Vivid Biosciences, is an unpaid board member for The Society for Functional Precision Medicine and he is currently collaborating with AstraZeneca. AV is cofounder of the Spin-off of Xenopat S.L and has ownership interests. The following are U.S. Patents regarding BH3 profiling owned by Dana-Farber: 10,393,733; 9,902,759; 9,856,303; 9,540,674; 8,221,966; and 7,868,133. JM is a co-inventor on a patent application WO2014047342A1 held/submitted by Dana-Farber Cancer Institute that covers dynamic BH3 profiling, licensed and with royalties paid. No potential conflicts of interest were disclosed by the other authors.
